Wells Fargo
MIRM icon

Wells Fargo’s Mirum Pharmaceuticals MIRM Stock Holding History

Wells Fargo’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.05M Buy
51,667
+34,044
+193% +$3.42M ﹤0.01% 2657
2026
Q1 		$1.63M Sell
17,623
-97,814
-85% -$9.2M ﹤0.01% 3420
2025
Q4 		$9.12M Buy
115,437
+88,372
+327% +$6.34M ﹤0.01% 2126
2025
Q3 		$1.98M Sell
27,065
-171,095
-86% -$10.9M ﹤0.01% 3308
2025
Q2 		$10.1M Buy
198,160
+164,492
+489% +$7.32M ﹤0.01% 1891
2025
Q1 		$1.52M Sell
33,668
-6,858
-17% -$323K ﹤0.01% 3377
2024
Q4 		$1.68M Sell
40,526
-67,501
-62% -$2.81M ﹤0.01% 3331
2024
Q3 		$4.21M Buy
108,027
+69,913
+183% +$2.79M ﹤0.01% 2479
2024
Q2 		$1.3M Buy
38,114
+30,239
+384% +$793K ﹤0.01% 3310
2024
Q1 		$198K Buy
7,875
+869
+12% +$23.9K ﹤0.01% 4474
2023
Q4 		$207K Sell
7,006
-23,213
-77% -$703K ﹤0.01% 4444
2023
Q3 		$955K Sell
30,219
-541
-2% -$14.8K ﹤0.01% 3364
2023
Q2 		$796K Buy
30,760
+12,835
+72% +$341K ﹤0.01% 3622
2023
Q1 		$431K Buy
+17,925
New +$409K ﹤0.01% 3948
2022
Q4 		– Sell
-737
Closed -$16K – 7618
2022
Q3 		$16K Buy
737
+284
+63% +$6.84K ﹤0.01% 5506
2022
Q2 		$9K Buy
+453
New +$10.7K ﹤0.01% 5797
2022
Q1 		– Sell
-21
Closed – – 7523
2021
Q4 		$0 Sell
21
-282
-93% -$4.39K ﹤0.01% 7587
2021
Q3 		$6K Sell
303
-31
-9% -$504 ﹤0.01% 6334
2021
Q2 		$6K Sell
334
-2,166
-87% -$38.8K ﹤0.01% 6289
2021
Q1 		$50K Sell
2,500
-16,538
-87% -$317K ﹤0.01% 5815
2020
Q4 		$332K Buy
19,038
+13,752
+260% +$270K ﹤0.01% 4811
2020
Q3 		$101K Sell
5,286
-1,212
-19% -$26K ﹤0.01% 5260
2020
Q2 		$126K Buy
6,498
+2,820
+77% +$47.1K ﹤0.01% 5118
2020
Q1 		$51K Buy
3,678
+3,443
+1,465% +$56.5K ﹤0.01% 5331
2019
Q4 		$5K Buy
235
+18
+8% +$192 ﹤0.01% 6040
2019
Q3 		$2K Buy
+217
New +$2.66K ﹤0.01% 6200

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo's MIRM Position: Q2 2026 in Review

Wells Fargo increased its Mirum Pharmaceuticals (MIRM) stake by 193% in Q2 2026, buying an estimated $3.42M and bringing the position to 51,667 shares worth $6.05M. The position accounts for ﹤0.01% of the portfolio, ranked #2657.

Wells Fargo first reported a position in MIRM in Q3 2019 and has held it in 26 quarters since. The position peaked at $10.1M in Q2 2025. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Wells Fargo held 51,667 shares of Mirum Pharmaceuticals worth $6.05M as of Q2 2026.
  • Wells Fargo bought 34,044 Mirum Pharmaceuticals shares in Q2 2026, an estimated $3.42M.
  • Mirum Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #2657 holding.
  • Wells Fargo first reported a position in Mirum Pharmaceuticals in Q3 2019 and has held it in 26 quarters since.
  • Wells Fargo's Mirum Pharmaceuticals position peaked at $10.1M in Q2 2025.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.